1 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [PMID: 20610543 DOI: 10.3322/ caac.20073]
2 Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, PéréVergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, MontotoGrillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]
3 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]
4 Sugiyama H. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. Expert Rev Vaccines 2005; 4: 503-512 [PMID: 16117707]
5 Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296 [PMID: 1910679]
6 Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426 [PMID: 17898760]
7 Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K, Uchiyama K, Satoh K, Ito M, Komita H, Arakawa H, Ohkusa T, Gong J, Tajiri H. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol 2011; 2011: 267539 [PMID: 21922022 DOI: 10.1155/2011/267539]
8 Hu HM, Winter H, Urba WJ, Fox BA. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000; 165: 4246-4253 [PMID: 11035058]
9 Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368 [PMID: 9858522]
10 Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Gong J, Sugiyama H, Ohkusa T, Tajiri H. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res 2014; 20: 4228-4239 [PMID: 25056373 DOI: 10.1158/1078-0432.CCR-14-0314]
11 Takakura K, Koido S, Kan S, Yoshida K, Mori M, Hirano Y, Ito Z, Kobayashi H, Takami S, Matsumoto Y, Kajihara M, Misawa T, Okamoto M, Sugiyama H, Homma S, Ohkusa T, Tajiri H. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer. Anticancer Res 2015; 35: 555-562 [PMID: 25550602]
12 Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-1648 [PMID: 23547081 DOI: 10.1200/jco.2012.43.3680]
13 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-172 [PMID: 20101258 DOI: 10.1038/nrclinonc.2009.236]
14 Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;
15: 7412-7420 [PMID: 19934295] 15 Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 2008; 57: 1559-1568 [PMID: 18618110 DOI: 10.1007/s00262-008-0553-y]
16 Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141: 125-139 [PMID: 24076269 DOI: 10.1016/j.pharmthera.2013.09.004]
17 Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14: e218-e228 [PMID: 23639322 DOI: 10.1016/s1470-2045(12)70582-x]
18 Roshani R, McCarthy F, Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett 2014; 345: 157-163 [PMID: 23879960 DOI: 10.1016/j.canlet.2013.07.014]
19 Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P, Mellado B. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate 2013; 73: 512-521 [PMID: 23038213 DOI: 10.1002/pros.22591]
20 Tang RF, Wang SX, Zhang FR, Peng L, Wang SX, Xiao Y, Zhang M. Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2005; 4: 460-463 [PMID: 16109537]
21 McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, Williams JD, Rose-John S, Jones SA, Topley N. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 2003; 112: 598-607 [PMID: 12925700 DOI: 10.1172/ jci17129]
22 Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N, Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 2003; 22: 765-771 [PMID: 12632066]
23 Li M, Zhang Y, Feurino LW, Wang H, Fisher WE, Brunicardi FC, Chen C, Yao Q. Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci 2008; 99: 733-737 [PMID: 18307536 DOI: 10.1111/j.1349-7006.2008.00740.x]
24 Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M, Emanuelli G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006; 55: 684-698 [PMID: 16094523 DOI: 10.1007/ s00262-005-0047-0]
25 Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P, Zhu MH. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 2012; 18: 1123-1129 [PMID: 22416189 DOI: 10.3748/wjg.v18.i10.1123]
26 Fujita Y, Okamoto M, Goda H, Tano T, Nakashiro K, Sugita A, Fujita T, Koido S, Homma S, Kawakami Y, Hamakawa H. Prognostic significance of interleukin-8 and CD163-positive cellinfiltration in tumor tissues in patients with oral squamous cell carcinoma. PLoS One 2014; 9: e110378 [PMID: 25461761 DOI: 10.1371/journal.pone.0110378]
論文の公開元へ
